Research programme: anti-glaucoma therapeutics - pSivida/Undisclosed company

Drug Profile

Research programme: anti-glaucoma therapeutics - pSivida/Undisclosed company

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator pSivida; Undisclosed
  • Class Antiglaucomas; Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma

Most Recent Events

  • 26 Sep 2017 pSivida and an undisclosed global pharmaceutical company agree to develop antiglaucoma therapeutics
  • 26 Sep 2017 Preclinical trials in Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top